Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Consensus Price Target from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been assigned a consensus recommendation of “Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $20.83.

Several equities analysts have weighed in on REPL shares. HC Wainwright lifted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Piper Sandler raised their target price on Replimune Group from $14.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, June 2nd. Finally, JPMorgan Chase & Co. upped their price target on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th.

Replimune Group Price Performance

NASDAQ REPL opened at $10.38 on Friday. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group has a 1 year low of $6.44 and a 1 year high of $17.00. The company has a market cap of $800.16 million, a PE ratio of -3.38 and a beta of 0.68. The stock’s 50-day moving average price is $8.38 and its two-hundred day moving average price is $11.04.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the firm earned ($0.25) EPS. On average, analysts predict that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling at Replimune Group

In other news, CAO Andrew Schwendenman sold 3,287 shares of the firm’s stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $26,460.35. Following the completion of the sale, the chief accounting officer now directly owns 68,284 shares of the company’s stock, valued at $549,686.20. This trade represents a 4.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Konstantinos Xynos sold 7,952 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the sale, the insider now owns 146,933 shares of the company’s stock, valued at approximately $1,184,279.98. This represents a 5.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds have recently added to or reduced their stakes in REPL. Sterling Capital Management LLC lifted its stake in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after acquiring an additional 1,655 shares during the last quarter. US Bancorp DE increased its stake in shares of Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after purchasing an additional 3,921 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after purchasing an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd raised its holdings in shares of Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after purchasing an additional 8,183 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Replimune Group by 897.2% in the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company’s stock valued at $902,000 after purchasing an additional 7,913 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.